Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
Conditions: Melanoma; Renal Cell Carcinoma; NSCLC; Hepatocellular Carcinoma; Urothelial Cancer; Gastric Adenocarcinoma; HNSCC; Esophageal Adenocarcinoma; Microsatellite Instability-High Solid Malignant Tumor Interventions: Drug: Nivolumab or Pembrolizumab (dependent upon approved indication); Drug: Metformin; Drug: Rosiglitazone Sponsor: Dan Zandberg Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenocarcinoma | Avandia | Cancer | Cancer & Oncology | Carcinoma | Fortamet | Gastroenterology | HNSCC | Melanoma | Metformin | Non-Small Cell Lung Cancer | Research | Skin Cancer